NewAmsterdam Pharma Company (NAMS) Q1 2024 Earnings
NAMS·Reported May 8, 2024·Before market open
NewAmsterdam Pharma Company reported Q1 2024 revenue of $1.5M, missed analyst consensus of $1.6M by $113.8K. Diluted EPS came in at $-0.62, missed the $-0.54 consensus by $0.08.
Revenue
$1.5Mmissed by $113.8K
Consensus: $1.6MDiluted EPS
$-0.62missed by $0.08
Consensus: $-0.54
Financial Snapshot
Trailing eight quarters through Q1 2024
Q1 2024 Earnings FAQ
Common questions about NewAmsterdam Pharma Company's Q1 2024 earnings report.
NewAmsterdam Pharma Company (NAMS) reported Q1 2024 earnings on May 8, 2024 before market open.
NewAmsterdam Pharma Company reported revenue of $1.5M and diluted EPS of $-0.62 for Q1 2024.
Revenue missed the consensus estimate of $1.6M by $113.8K. EPS missed the consensus estimate of $-0.54 by $0.08.
You can read the 10-Q periodic report (0000950170-24-055767) directly on SEC EDGAR. The filing index links above go to sec.gov.